Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Completed · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

BMS-820132 is an investigational new drug being developed by BMS for treating Type 2 diabetes. The purpose of this study is to test the safety/tolerability (potential side effects) of multiple doses of the investigational new drug, as well as the amount of study drug in the blood and its effects on blood sugar,in subjects with type 2 diabetes.

Key facts

Study ID

NCT01290575

Run by

Bristol-Myers Squibb

People needed

67

Starts

2011-02-01

Expected to finish

2011-11-01

Last updated by the study team

2012-03-27

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females of childbearing potential (willing to use an acceptable method of contraception), or females of non-childbearing potential (i.e., post-menopausal or surgically sterile).
• Diagnosis of type 2 diabetes treated with metformin monotherapy (at least 1500 mg/day for at least 6 months) on a stable regimen for at least 2 months.
• Body Mass Index (BMI) of 18.5 to 40 kg/m2.
• Fasting glucose in the range of 125-275 mg/dL.
• Hemoglobin A1c (HbA1c) in the range of 7.0% -11.0%.
• Fasting C-peptide > 1 ng/mL.

You may not qualify if…

• Clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations, and any significant acute or chronic medical illness other than stable and well controlled hypertension, microalbuminuria, dyslipidemia, depression, or hypothyroidism.
• History of diabetic ketoacidosis, hyperosmolar nonketotic syndrome, lactic acidosis, hypoglycemia (i.e., ≥ 1 self-reported episodes of hypoglycemia within the last 3 months or ≥ 2 self-reported episodes of hypoglycemia within the last 6 months), or hypoglycemia unawareness.
• Any major surgery within 4 weeks of study drug administration.
• Any gastrointestinal surgery that could impact upon the absorption of study drug.
• Smoking more than 10 cigarettes per day.
• Recent drug or alcohol abuse.
• Women who are pregnant or breastfeeding.
• Positive urine screen for drugs of abuse.
• Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human Immunodeficiency Virus (HIV)-1, -2 antibody.

Where it is running

• Dedicated Phase I, Inc. — Phoenix, Arizona, United States
• Osborne Research Center — Little Rock, Arkansas, United States
• Clinical Pharmacology Of Miami Inc. — Miami, Florida, United States
• Mra Clinical Research — Miami, Florida, United States
• Cetero Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.